SCHEMBL530709

SCHEMBL530709

CCCCCC1(N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21417322 0.97 TSHR (0.42)
SCHEMBL30337031 0.92 TSHR (0.33)
SCHEMBL895638 0.92
SCHEMBL9209531 0.90 TSHR (0.33)
SCHEMBL5821040 0.90 TSHR (0.33)
SCHEMBL9207554 0.87 TSHR (0.38)
SCHEMBL9213238 0.87 TSHR (0.38)
SCHEMBL1485557 0.87 TSHR (0.38)
SCHEMBL9212311 0.87 TSHR (0.38)
SCHEMBL9202179 0.87 TSHR (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221569-A Cyclopentane-1, 2-diamine derivative and preparation method thereof 浙江大学 2024-06-21 CN claimed
CN-110467532-B Synthetic method of aryl cyclopropylamine compound 华东理工大学 2020-09-29 CN claimed
EP-3133059-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE Oryzon Genomics, S.A. (ES) 2017-02-22 EP claimed
EP-2560947-B1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS SA (ES) 2016-10-12 EP claimed
US-20150368186-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS S.A. 2015-12-24 US claimed
US-9149447-B2 Lysine specific demethylase-1 inhibitors and their use ORYZON GENOMICS S.A. (ES) 2015-10-06 US claimed
US-20140213657-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS S.A. (ES) 2014-07-31 US claimed
US-20140163041-A1 LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS ORYZON GENOMICS S.A. (ES) 2014-06-12 US claimed
US-20130090386-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS S.A. 2013-04-11 US claimed
EP-2560947-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE Oryzon Genomics, S.A. (ES) 2013-02-27 EP claimed
WO-2011131697-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS S.A. (ES) 2011-10-27 WO claimed
WO-2006102308-A2 BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS AZEVAN PHARMACEUTICALS, INC. (US) 2006-09-28 WO claimed
EP-4433453-A1 NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS Icagen, LLC (US) 2024-09-25 EP disclosed
EP-3668877-B1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2024-05-01 EP disclosed
EP-4349408-A2 METHODS FOR TREATING PROTEINOPATHIES Genzyme Corporation (US) 2024-04-10 EP disclosed
EP-3267983-B1 METHODS FOR TREATING PROTEINOPATHIES GENZYME CORP (US) 2023-12-20 EP disclosed
EP-1529031-A1 ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS Aventis Pharma Deutschland GmbH (DE) 2005-05-11 EP disclosed
US-20040082628-A1 Acylated arylcycloalkylamines and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-04-29 US disclosed
WO-2004014842-A1 ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-19 WO disclosed
EP-1388535-A1 Acylated arylcycloalkylamines and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (DE) 2004-02-11 EP disclosed